Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression

Metastatic Breast Cancer Clinical Trial

— FAIM  

Official title:

Randomised Phase II Study of Induction Fulvestrant and CDK4/6 Inhibition With the Addition of Ipatasertib in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04920708
• Other study ID #: CCR5214
• Status: Recruiting
• Phase: Phase 2
• Start date: December 28, 2022
• Est. completion date: September 2026

Study information

• Verified date: October 2023
• Source: Royal Marsden NHS Foundation Trust
• Contact: Project Manager
• Phone: 020 7808 2887
• Email: faim[@]rmh.nhs.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Analysis of circulating tumour DNA (ctDNA) found in a patient's peripheral blood can identify cancer progression and predict a patient's response to therapy. By using ctDNA analysis and imaging techniques, the FAIM trial aims to determine whether the addition of the experimental drug ipatasertib to a standard combination of the hormone treatment fulvestrant and the targeted agent palbociclib increases progression free survival (PFS) for patients with hormone-receptor positive and human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer.

Description:

Circulating tumour DNA (ctDNA) can be found in the peripheral blood of patients with cancer. ctDNA analysis provides a readily available, serial source of tumour DNA which can be used to monitor disease and predict a patients response to therapy. Relative changes in ctDNA after 15 days of treatment with palbociclib and fulvestrant has been found to strongly predict progression free survival (PFS) in hormone-receptor positive and human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer patients: patients without ctDNA suppression after 2 weeks of treatment had a significantly shorter PFS compared to those with ctDNA suppression, identifying a group of patients who require additional therapy to prevent early progression. The FAIM trial is a randomised, open-label study which will aim to determine whether the addition of ipatasertib to standard of care CDK4/6 inhibitors + fulvestrant increases PFS in patients who lack ctDNA suppression after 15 days of treatment. Patients starting standard of care CDK4/6 inhibitors + fulvestrant will have a ctDNA assessment on cycle 1 day 1 (C1D1) and cycle 1 day 15 (C1D15). Those with high ctDNA levels at C1D15 will be randomised on a 1:1 basis to either standard of care (CDK4/6 inhibitors + fulvestrant) or standard of care plus the experimental drug ipatasertib (CDK4/6 inhibitor + fulvestrant + ipatasertib). Patients with ctDNA suppression at C1D15 will continue standard of care (fulvestrant+CDK4/6 inhibitor); the first 100 patients of this group will be followed for PFS and ctDNA collection. Patients without detectable ctDNA on C1D1 will be followed and treated according standard of care; the first 50 patients of this group will be followed for PFS, overall survival (OS), time to next treatment, and time to chemotherapy. Progression free survival will be monitored using RECIST 1.1.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 324
• Est. completion date: September 2026
• Est. primary completion date: September 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histological diagnosis of metastatic or inoperable locally advanced ER positive/HER2 negative breast cancer. Assessment of ER and HER2 status as per local assessment. Histologically proven primary ER+ (Allred score 3/8 or greater, or stain in >1% of cancer cells) and HER2- (immunohistochemistry 0/1+ or negative by in situ hybridization) breast cancer as determined by local laboratory.

2. Be willing to consent for an archival tumour tissue sample (of advanced disease) to be requested for transfer to the Royal Marsden for future review during study screening. Patients without a metastatic biopsy may be eligible if archival tumour from the breast primary tumour is available, but only after discussion with the Chief Investigator.

3. Previously treated with no more than one prior line of chemotherapy for advanced disease.

4. Patients eligible according to standard of care for fulvestrant in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib).

5. Patients must have received at least one prior line of hormone therapy for advanced disease and progressed on or within 1 month from stopping prior endocrine therapy for advanced disease, or relapsed on or within 12 months of completing adjuvant endocrine therapy.

6. Measurable disease (RECIST 1.1) or assessable bone disease (lytic or mixed lytic sclerotic).

7. Eastern Cooperative Oncology Group (ECOG) performance status 0,1 or 2.

8. Estimated life expectancy of at least 3 months.

9. Adequate bone marrow, renal, and liver function within 14 days before the first study

treatment on Day 1 of Cycle 1, defined by the following:

1. Neutrophils (ANC = 1500/µL), Haemoglobin =9 g/dL, Platelet count =100,000/µL

2. Serum albumin =3 g/dL

3. Total bilirubin =1.5 x the upper limit of normal (ULN), with the following exception: patients with known Gilbert syndrome who have serum bilirubin =3 x ULN may be enrolled

4. AST and ALT =2.5 x ULN, with the following exception: patients with documented liver or bone metastases may have AST and ALT =5 x ULN.

5. ALP =2 x ULN, with the following exceptions: patients with known liver involvement may have ALP =5 x ULN, patients with known bone involvement may have ALP =7 x ULN

6. Serum creatinine =1.5 x ULN or creatinine clearance =50 mL/min on the basis of the Cockcroft-Gault glomerular filtration rate estimation.

7. INR <1.5 x ULN and aPTT <1.5 x ULN. Patients requiring formal anticoagulation should receive either low-molecular weight heparin or a direct oral anticoagulant.

10. Fasting glucose =150mg/dL and HbA1c =7.5%.

11. Negative serum pregnancy test at screening (females of childbearing potential).

12. Patients able to have children must agree to use two highly effective methods of contraception throughout the study and for 2 years after last dose of fulvestrant and at least two years after last dose. Patients must additionally agree to refrain from donating eggs during this period.

13. Signed and dated informed consent.

14. Patients willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other procedures.

15. Pre/peri-menopausal patients must be treated with GnRH agonist beginning at least 7 days prior to Day 1 of Cycle 1 and continuing every 28 days for the duration of study treatment.

Exclusion Criteria:

1. Previous fulvestrant and/or CDK4/6 inhibitor (abemaciclib, palbociclib or ribociclib) in any setting.

2. Prior use of AKT inhibitor (any setting).

3. History of malabsorption syndrome or other condition that would interfere with enteral absorption or results in the inability or unwillingness to swallow pills.

4. Systemic chemotherapy within 14 days prior to study entry.

5. Major surgery within 4 weeks or radiation therapy within 14 days prior to study entry.

6. Patients with known leptomeningeal disease, symptomatic brain metastases requiring steroids, untreated brain metastases or spinal cord compression.

7. Clinically significant, uncontrolled heart disease and/or cardiac repolarization

abnormality including any of the following:

1. History of angina pectoris, symptomatic pericarditis, coronary artery bypass graft (CABG) or myocardial infarction within 12 months prior to study entry.

2. Known (documented) cardiomyopathy, i.e known left ventricular ejection fraction (LVEF) < 50% (ECHO or MUGA not needed specifically for this trial).

3. History of symptomatic cardiac failure (NYHA class II-IV or LVEF <50%), uncontrolled hypertension, cardiac dysrhythmia including atrial fibrillation requiring medication, significant/symptomatic bradycardia, Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome or any of the following:, cerebrovascular accident, or transient ischemic attack within 12 months; known risk factors for prolonged QT interval or Torsade's de Pointes; Uncorrected hypomagnesaemia or hypokalaemia of Grade 3 or higher; Systolic Blood Pressure (SBP) >160 mmHg or <90 mmHg; Bradycardia (heart rate <50 at rest), by ECG (based on a mean of 3 ECGs) or pulse; On screening, QTcF >470 screening ECG (based on a mean of 3 ECGs).

8. Pneumonitis, interstitial lung disease or pulmonary fibrosis.

9. Type I or II diabetes requiring insulin.

10. Use of drugs that are known potent cytochrome P450 3A inducers or inhibitors within 2 weeks or 5 elimination half-lives (whichever is longer) before the first dose of study drug.

11. Known HIV or AIDS-related illness.

12. Active infection requiring systemic therapy.

13. Known positive HBV or HCV test indicating acute or chronic infection

1. Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as having a negative HBsAg test and a positive hepatitis B core antibody [HBcAb] test, accompanied by a negative HBV DNA test) are eligible.

2. Patients positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.

14. Clinically significant liver disease consistent with Child Pugh class B or C.

15. Administration of a live vaccine within 4 weeks prior to study entry.

16. Diagnosis of other malignancy within 5 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or cervix.

17. Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry and/or during study participation.

18. Persisting toxicity related to prior therapy >Grade 1 (except for stable peripheral neuropathy grade 2 or alopecia grade 2).

19. Other severe acute or chronic medical condition, including colitis, inflammatory bowel disease, psychiatric condition, recent or active suicidal ideation or behaviour, or end stage renal disease on haemodialysis, or laboratory abnormality that may increase the risk associated with study participation or investigational products administration or may interfere with the interpretation of results and, in the judgment of the Investigator, would make the patient inappropriate study entry.

20. Radiation therapy (other than palliative radiation to bony metastases) as cancer therapy within 4 weeks prior to initiation of study treatment.

21. Palliative radiation to bony metastases within 2 weeks prior to initiation of study treatment.

22. Allergy or hypersensitivity to components of the ipatasertib, palbociclib, or fulvestrant.

23. Patients able to have children who are unwilling or unable to use 2 highly effective method(s)¹ of contraception for the duration of the study and for at least 60 days after the last dose of investigational product. Patient pregnant or breastfeeding.

24. Need for chronic corticosteroid therapy of >10 mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids or immunosuppressants for a chronic disease.

Related Conditions & MeSH terms

• Advanced Breast Cancer
• Breast Neoplasms
• ER+ Breast Cancer
• Metastatic Breast Cancer

Intervention

Drug:
• Ipatasertib 300mg
Ipatasertib 300mg once daily. Oral administration. Treatment is continuous daily for 21 days, followed by 7 days off, to complete a 28 day cycle.
• Fulvestrant 500g
Fulvestrant 500mg administered intramuscularly in the buttocks slowly (1-2 minutes per injection) as two 5-mL injections (one in each buttock). Administered days 1 and 15 of Cycle 1. For subsequent cycles, patients will receive fulvestrant as described above in the clinic on Day 1 of each cycle or approximately every 4 weeks.
• Palbociclib 75mg-125mg
Palboclicib 75mg-125mg once daily, dependent on toxicities. Oral administration. Treatment is continuous daily for 21 days, followed by 7 days off, to complete a 28 day cycle.
• CDK4/6 Inhibitor
CDK4/6 inhibitor. As per current standard of care regime for ER+/HER2- breast cancer.

Locations

Country	Name	City	State
United Kingdom	Addenbrookes Hospital	Cambridge	Cambridgeshire
United Kingdom	Velindre Cancer Centre	Cardiff	Wales
United Kingdom	Western General Hospital	Edinburgh
United Kingdom	Beatson West of Scotland Cancer Centre	Glasgow
United Kingdom	Royal Surrey NHS Foundation Trust	Guildford
United Kingdom	University Hospitals of Leicester NHS Trust	Leicester
United Kingdom	Clatterbridge Cancer Centre	Liverpool
United Kingdom	Guy's and St Thomas's NHS Foundation Trust	London
United Kingdom	Imperial College University Hospitals NHS Trust	London
United Kingdom	Mount Vernon Cancer Centre	London	Surrey
United Kingdom	Royal Free Hospital	London
United Kingdom	Royal Marsden NHS Foundation Trust	London
United Kingdom	University College London Hospital	London
United Kingdom	Maidstone Oncology Centre	Maidstone
United Kingdom	The Christie NHS Foundation Trust	Manchester
United Kingdom	Nottingham City Hospital	Nottingham
United Kingdom	Southampton Hospitals NHS Trust	Southampton
United Kingdom	Royal Cornwall Hospital	Truro	Cornwall

Sponsors (3)

Lead Sponsor	Collaborator
Royal Marsden NHS Foundation Trust	Hoffmann-La Roche, Pfizer

Country where clinical trial is conducted

United Kingdom, 

References & Publications (15)

Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014 Feb 19;6(224):224ra24. doi: 10.1126/scitranslmed.3007094. — View Citation

Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, Andre F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortes J, Curigliano G, Dieras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)dagger. Ann Oncol. 2018 Aug 1;29(8):1634-1657. doi: 10.1093/annonc/mdy192. No abstract available. — View Citation

Coudreuse D, Nurse P. Driving the cell cycle with a minimal CDK control network. Nature. 2010 Dec 23;468(7327):1074-9. doi: 10.1038/nature09543. — View Citation

Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Zhang K, Theall KP, Jiang Y, Bartlett CH, Koehler M, Slamon D. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016 Apr;17(4):425-439. doi: 10.1016/S1470-2045(15)00613-0. Epub 2016 Mar 3. Erratum In: Lancet Oncol. 2016 Apr;17 (4):e136. Lancet Oncol. 2016 Jul;17 (7):e270. — View Citation

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013 Apr;49(6):1374-403. doi: 10.1016/j.ejca.2012.12.027. Epub 2013 Feb 26. — View Citation

Johnston SR. Enhancing the efficacy of hormonal agents with selected targeted agents. Clin Breast Cancer. 2009 Jun;9 Suppl 1:S28-36. doi: 10.3816/CBC.2009.s.003. — View Citation

Meyerson M, Harlow E. Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol. 1994 Mar;14(3):2077-86. doi: 10.1128/mcb.14.3.2077-2086.1994. — View Citation

Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009 Sep;9(9):631-43. doi: 10.1038/nrc2713. — View Citation

O'Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 2016 Jul;13(7):417-30. doi: 10.1038/nrclinonc.2016.26. Epub 2016 Mar 31. — View Citation

O'Leary B, Hrebien S, Morden JP, Beaney M, Fribbens C, Huang X, Liu Y, Bartlett CH, Koehler M, Cristofanilli M, Garcia-Murillas I, Bliss JM, Turner NC. Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. Nat Commun. 2018 Mar 1;9(1):896. doi: 10.1038/s41467-018-03215-x. — View Citation

Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Frenzel M, Lin Y, Barriga S, Smith IC, Bourayou N, Llombart-Cussac A. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017 Sep 1;35(25):2875-2884. doi: 10.1200/JCO.2017.73.7585. Epub 2017 Jun 3. — View Citation

Telli ML, Gradishar WJ, Ward JH. NCCN Guidelines Updates: Breast Cancer. J Natl Compr Canc Netw. 2019 May 1;17(5.5):552-555. doi: 10.6004/jnccn.2019.5006. — View Citation

Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M; PALOMA3 Study Group. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015 Jul 16;373(3):209-19. doi: 10.1056/NEJMoa1505270. Epub 2015 Jun 1. — View Citation

Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Andre F, Puyana Theall K, Huang X, Giorgetti C, Huang Bartlett C, Cristofanilli M. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2018 Nov 15;379(20):1926-1936. doi: 10.1056/NEJMoa1810527. Epub 2018 Oct 20. — View Citation

Zardavas D, Irrthum A, Swanton C, Piccart M. Clinical management of breast cancer heterogeneity. Nat Rev Clin Oncol. 2015 Jul;12(7):381-94. doi: 10.1038/nrclinonc.2015.73. Epub 2015 Apr 21. — View Citation

* Note: There are 15 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Evaluate changes in ctDNA in patients with high ctDNA C1D15	• To evaluate changes in ctDNA in patients randomised to palbociclib/fulvestrant/ipatasertib or standard of care palbociclib/fulvestrant alone.	36 months (treatment duration + follow-up duration)
Other	Compare progression free survival (PFS) in patients with high ctDNA at C1D15 and genetic alterations identified in ctDNA sequencing.	• To compare PFS in patients randomised between SOC palbociclib/fulvestrant + /ipatasertib and SOC palbociclib/fulvestrant alone, in subgroups of advanced ER+/HER2- breast cancer patients with genetic alterations identified in ctDNA sequencing data.	36 months (treatment duration + follow-up duration)
Other	Report progression free survival (PFS) in patients with undetectable ctDNA and those with detected ctDNA at C1D1 with and without suppression at C1D15.	• To compare report PFS in patients with undetectable ctDNA at Cycle 1 Day 1 and those with detectable ctDNA with and without ctDNA suppression at Day 15.	36 months (treatment duration + follow-up duration)
Primary	Assess progression free survival (PFS)	To compare PFS in patients randomised between palbociclib/fulvestrant/ipatasertib versus standard of care palbociclib-fulvestrant alone, in advanced ER+/HER2- breast cancer patients with trackable mutations and high ctDNA after 2 weeks of CDK4/6 inhibitor/fulvestrant.	Time from date of randomisation until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 38 months
Secondary	Use NCI CTCAE V5.0 to assess safety and tolerability of palbociclib/fulvestrant/ipatasertib compared to palbociclib/fulvestrant alone	• To assess the overall safety and tolerability of palbociclib/fulvestrant/ipatasertib compared to standard of care palbociclib/fulvestrant alone. Safety will be evaluated continuously using NCI CTCAE V5.0.	36 months (treatment duration + follow-up duration)
Secondary	Assess overall survival	• To assess overall survival in patients receiving palbociclib/fulvestrant/ipatasertib compared to standard of care palbociclib/fulvestrant alone	36 months (treatment duration + follow-up duration)
Secondary	Assess objective response rate	• To assess the objective response rate in patients receiving palbociclib/fulvestrant/ipatasertib compared to standard of care palbociclib/fulvestrant alone	36 months (treatment duration + follow-up duration)
Secondary	Report progression free survival (PFS) in patients with low ctDNA and high ctDNA	• To report PFS in patients with high ctDNA randomised to standard of care palbociclib/fulvestrant alone with those with suppressed ctDNA on standard of care CDK4/6 inhibitor/fulvestrant alone (observational arm)	Time from date of randomisation until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 38 months
Secondary	Compare progression free survival (PFS) in the subgroup of advanced ER+/HER2- breast cancer patients	o compare PFS in patients randomised between palbociclib/fulvestrant/ipatasertib and palbociclib/fulvestrant alone, in the subgroup of advanced ER+/HER2- breast cancer patients with PIK3CA/PTEN/AKT1 mutations or PTEN loss and high ctDNA on palbociclib/fulvestrant	Time from date of randomisation until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 38 months